Sensus Healthcare, Inc. (NASDAQ:SRTS – Get Rating) CEO Joseph C. Sardano sold 36,093 shares of Sensus Healthcare stock in a transaction on Tuesday, August 9th. The stock was sold at an average price of $13.97, for a total transaction of $504,219.21. Following the sale, the chief executive officer now owns 1,294,200 shares in the company, valued at $18,079,974. The sale was disclosed in a document filed with the SEC, which is available through this link.
Sensus Healthcare Trading Up 6.2 %
SRTS stock opened at $14.97 on Friday. The company has a market capitalization of $249.70 million, a P/E ratio of 9.91 and a beta of 0.78. The business has a 50 day simple moving average of $9.63 and a 200-day simple moving average of $9.30. Sensus Healthcare, Inc. has a twelve month low of $3.21 and a twelve month high of $15.25.
Get Sensus Healthcare alerts:Institutional Trading of Sensus Healthcare
Institutional investors and hedge funds have recently bought and sold shares of the business. Bailard Inc. raised its holdings in shares of Sensus Healthcare by 3.9% in the second quarter. Bailard Inc. now owns 34,600 shares of the company's stock valued at $266,000 after buying an additional 1,300 shares during the last quarter. Northwestern Mutual Wealth Management Co. raised its stake in shares of Sensus Healthcare by 83.3% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 5,500 shares of the company's stock worth $40,000 after purchasing an additional 2,500 shares during the last quarter. Northern Trust Corp raised its holdings in Sensus Healthcare by 15.0% during the first quarter. Northern Trust Corp now owns 24,602 shares of the company's stock worth $249,000 after purchasing an additional 3,203 shares in the last quarter. Sheaff Brock Investment Advisors LLC lifted its position in Sensus Healthcare by 16.3% in the first quarter. Sheaff Brock Investment Advisors LLC now owns 25,264 shares of the company's stock valued at $255,000 after purchasing an additional 3,550 shares during the period. Finally, State Street Corp boosted its holdings in Sensus Healthcare by 8.9% in the 1st quarter. State Street Corp now owns 46,052 shares of the company's stock valued at $466,000 after purchasing an additional 3,765 shares in the last quarter. Hedge funds and other institutional investors own 20.49% of the company's stock.
Wall Street Analyst Weigh In
Separately, Maxim Group reaffirmed a "buy" rating and set a $14.00 price objective on shares of Sensus Healthcare in a report on Friday, May 6th.Sensus Healthcare Company Profile
(Get Rating)
Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy (SRT), a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a SRT-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.
Featured Stories
- Get a free copy of the StockNews.com research report on Sensus Healthcare (SRTS)
- 2 Important Retail Stock Battles to Watch
- MarketBeat: Week in Review 8/8 – 8/12
- What Is WallStreetBets and What Stocks Are They Targeting?
- Institutions And Analysts Propel Jack In The Box Higher
- Can You Guess Which EV Stock Is Beating Tesla ?
Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.